Wound Healing Complications Following Guided Bone Regeneration for Ridge Augmentation: A Systematic Review and Meta-Analysis
The rate of developing soft tissue complications that accompany guided bone regeneration (GBR) procedures varies widely, from 0% to 45%. The present review was conducted to investigate the rate for resorbable versus nonresorbable membranes and the timing of soft tissue complications. Electronic and...
Uloženo v:
| Vydáno v: | The International journal of oral and maxillofacial implants Ročník 33; číslo 1; s. 41–50 |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
01.01.2018
|
| Témata: | |
| ISSN: | 1942-4434, 1942-4434 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | The rate of developing soft tissue complications that accompany guided bone regeneration (GBR) procedures varies widely, from 0% to 45%. The present review was conducted to investigate the rate for resorbable versus nonresorbable membranes and the timing of soft tissue complications.
Electronic and manual literature searches were conducted by two independent reviewers using several databases, including MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and Cochrane Oral Health Group Trials Register, for articles published through July 2015, with no language restriction. Articles were included if they were clinical trials aimed at demonstrating the incidence of soft tissue complications following GBR procedures.
Overall, 21 and 15 articles were included in the qualitative and quantitative synthesis, respectively. The weighted complication rate of the overall soft tissue complications, including membrane exposure, soft tissue dehiscence, and acute infection/abscess, into the calculation was 16.8% (95% CI = 10.6% to 25.4%). When considering the complication rate based on membrane type used, resorbable membrane was associated with a weighted complication rate of 18.3% (95% CI: 10.4% to 30.4%) and nonresorbable membrane with a rate of 17.6% (95% CI: 10.0% to 29.3%). Moreover, soft tissue lesions were reported as early as 1 week and as late as 6 months based on the included studies.
Soft tissue complications after GBR are common (16.8%). Membrane type did not appear to significantly affect the complication rate, based on the limited number of data retrieved in this study. Technique sensitivity (ie, soft tissue management) may still be regarded as the main component to avoid soft tissue complications and, hence, to influence the success of bone regenerative therapy. |
|---|---|
| AbstractList | The rate of developing soft tissue complications that accompany guided bone regeneration (GBR) procedures varies widely, from 0% to 45%. The present review was conducted to investigate the rate for resorbable versus nonresorbable membranes and the timing of soft tissue complications.
Electronic and manual literature searches were conducted by two independent reviewers using several databases, including MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and Cochrane Oral Health Group Trials Register, for articles published through July 2015, with no language restriction. Articles were included if they were clinical trials aimed at demonstrating the incidence of soft tissue complications following GBR procedures.
Overall, 21 and 15 articles were included in the qualitative and quantitative synthesis, respectively. The weighted complication rate of the overall soft tissue complications, including membrane exposure, soft tissue dehiscence, and acute infection/abscess, into the calculation was 16.8% (95% CI = 10.6% to 25.4%). When considering the complication rate based on membrane type used, resorbable membrane was associated with a weighted complication rate of 18.3% (95% CI: 10.4% to 30.4%) and nonresorbable membrane with a rate of 17.6% (95% CI: 10.0% to 29.3%). Moreover, soft tissue lesions were reported as early as 1 week and as late as 6 months based on the included studies.
Soft tissue complications after GBR are common (16.8%). Membrane type did not appear to significantly affect the complication rate, based on the limited number of data retrieved in this study. Technique sensitivity (ie, soft tissue management) may still be regarded as the main component to avoid soft tissue complications and, hence, to influence the success of bone regenerative therapy. The rate of developing soft tissue complications that accompany guided bone regeneration (GBR) procedures varies widely, from 0% to 45%. The present review was conducted to investigate the rate for resorbable versus nonresorbable membranes and the timing of soft tissue complications.PURPOSEThe rate of developing soft tissue complications that accompany guided bone regeneration (GBR) procedures varies widely, from 0% to 45%. The present review was conducted to investigate the rate for resorbable versus nonresorbable membranes and the timing of soft tissue complications.Electronic and manual literature searches were conducted by two independent reviewers using several databases, including MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and Cochrane Oral Health Group Trials Register, for articles published through July 2015, with no language restriction. Articles were included if they were clinical trials aimed at demonstrating the incidence of soft tissue complications following GBR procedures.MATERIALS AND METHODSElectronic and manual literature searches were conducted by two independent reviewers using several databases, including MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and Cochrane Oral Health Group Trials Register, for articles published through July 2015, with no language restriction. Articles were included if they were clinical trials aimed at demonstrating the incidence of soft tissue complications following GBR procedures.Overall, 21 and 15 articles were included in the qualitative and quantitative synthesis, respectively. The weighted complication rate of the overall soft tissue complications, including membrane exposure, soft tissue dehiscence, and acute infection/abscess, into the calculation was 16.8% (95% CI = 10.6% to 25.4%). When considering the complication rate based on membrane type used, resorbable membrane was associated with a weighted complication rate of 18.3% (95% CI: 10.4% to 30.4%) and nonresorbable membrane with a rate of 17.6% (95% CI: 10.0% to 29.3%). Moreover, soft tissue lesions were reported as early as 1 week and as late as 6 months based on the included studies.RESULTSOverall, 21 and 15 articles were included in the qualitative and quantitative synthesis, respectively. The weighted complication rate of the overall soft tissue complications, including membrane exposure, soft tissue dehiscence, and acute infection/abscess, into the calculation was 16.8% (95% CI = 10.6% to 25.4%). When considering the complication rate based on membrane type used, resorbable membrane was associated with a weighted complication rate of 18.3% (95% CI: 10.4% to 30.4%) and nonresorbable membrane with a rate of 17.6% (95% CI: 10.0% to 29.3%). Moreover, soft tissue lesions were reported as early as 1 week and as late as 6 months based on the included studies.Soft tissue complications after GBR are common (16.8%). Membrane type did not appear to significantly affect the complication rate, based on the limited number of data retrieved in this study. Technique sensitivity (ie, soft tissue management) may still be regarded as the main component to avoid soft tissue complications and, hence, to influence the success of bone regenerative therapy.CONCLUSIONSoft tissue complications after GBR are common (16.8%). Membrane type did not appear to significantly affect the complication rate, based on the limited number of data retrieved in this study. Technique sensitivity (ie, soft tissue management) may still be regarded as the main component to avoid soft tissue complications and, hence, to influence the success of bone regenerative therapy. |
| Author | Lin, Guo-Hao Lim, Glendale Chan, Hsun-Liang Monje, Alberto Wang, Hom-Lay |
| Author_xml | – sequence: 1 givenname: Glendale surname: Lim fullname: Lim, Glendale – sequence: 2 givenname: Guo-Hao surname: Lin fullname: Lin, Guo-Hao – sequence: 3 givenname: Alberto surname: Monje fullname: Monje, Alberto – sequence: 4 givenname: Hsun-Liang surname: Chan fullname: Chan, Hsun-Liang – sequence: 5 givenname: Hom-Lay surname: Wang fullname: Wang, Hom-Lay |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28938030$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkF9LwzAUxYNM3B998QNIHn3pTJq2aX2rw23CRJiKjyVNbktGm8ymdQz88HZzgk_33MPv3gNnjAbGGkDompIppRHhdxtb62kYxvQMjWgS-F4QsGDwTw_R2LkNIT6lxL9AQz9OWEwYGaHvD9sZhZcgKm1KPLP1ttJStNoah-e2quzu4C86rUDhhz4Yr6EEA82RwYVt8FqrEnDalTWY9mjf4xS_7l0Ldb_K_uJLww6LPugZWuGlRlR7p90lOi9E5eDqNCfoff74Nlt6q5fF0yxdeZKFrPWiOGJ5LGNS0IBJQpQfciaCgicREB7lYaK4oExKVkgouOLST2gQ5gyEYIwTf4Juf_9uG_vZgWuzWjsJVSUM2M5lh544izg7oDcntMtrUNm20bVo9tlfY_4PlEpvhg |
| CitedBy_id | crossref_primary_10_1111_jre_13266 crossref_primary_10_4012_dmj_2024_371 crossref_primary_10_1007_s00784_023_05108_w crossref_primary_10_1016_j_jcms_2022_06_008 crossref_primary_10_3390_coatings11030316 crossref_primary_10_1016_j_ijbiomac_2022_01_147 crossref_primary_10_1007_s42242_020_00108_1 crossref_primary_10_1016_j_prosdent_2022_02_021 crossref_primary_10_1111_jcpe_13057 crossref_primary_10_1016_j_jdent_2023_104735 crossref_primary_10_1155_2023_6614653 crossref_primary_10_1002_JPER_22_0030 crossref_primary_10_3390_bioengineering11020192 crossref_primary_10_1002_cre2_849 crossref_primary_10_1186_s12903_022_02513_7 crossref_primary_10_1016_j_peptides_2023_171074 crossref_primary_10_1016_j_bioadv_2024_214146 crossref_primary_10_3390_medicina61010058 crossref_primary_10_1111_cid_13282 crossref_primary_10_1002_cap_10144 crossref_primary_10_3390_app10082659 crossref_primary_10_3390_jcm11154598 crossref_primary_10_1111_prd_12509 crossref_primary_10_1002_adfm_202214657 crossref_primary_10_1111_clr_13841 crossref_primary_10_1002_cre2_344 crossref_primary_10_1021_acsabm_5c00263 crossref_primary_10_1111_prd_12502 crossref_primary_10_3389_fbioe_2021_676874 crossref_primary_10_1002_cre2_902 crossref_primary_10_1002_JPER_18_0629 crossref_primary_10_1177_08853282221132351 crossref_primary_10_3390_ma14216642 crossref_primary_10_1155_2021_9931505 crossref_primary_10_3390_jcm11164739 crossref_primary_10_1002_JPER_23_0370 crossref_primary_10_3390_jcm10173953 crossref_primary_10_1111_cid_12940 crossref_primary_10_1111_cid_13113 crossref_primary_10_3390_app12125889 crossref_primary_10_1007_s00784_024_06007_4 crossref_primary_10_3390_healthcare9030315 crossref_primary_10_1111_prd_12479 crossref_primary_10_1111_prd_12518 crossref_primary_10_3390_pharmaceutics15122725 crossref_primary_10_1111_prd_12472 crossref_primary_10_2174_0118742106356292241122070017 crossref_primary_10_1007_s00784_023_05141_9 crossref_primary_10_1016_j_jdent_2021_103780 crossref_primary_10_1111_clr_14363 crossref_primary_10_1016_j_bioactmat_2020_09_019 crossref_primary_10_1002_cap_10228 crossref_primary_10_3390_medicina59101698 crossref_primary_10_3390_medicina61071269 crossref_primary_10_3390_biomimetics10030165 crossref_primary_10_1016_j_jebdp_2018_03_010 crossref_primary_10_1002_adhm_202304128 crossref_primary_10_1002_JPER_19_0186 crossref_primary_10_3390_biomimetics10060386 crossref_primary_10_1016_j_prosdent_2019_05_010 crossref_primary_10_1016_j_bioadv_2022_212976 crossref_primary_10_1111_cid_12966 crossref_primary_10_1111_prd_12481 crossref_primary_10_1111_cid_13014 crossref_primary_10_3390_jcm14124284 crossref_primary_10_1007_s00784_022_04596_6 crossref_primary_10_1155_2022_7742687 crossref_primary_10_1007_s10266_022_00705_9 crossref_primary_10_1111_prd_12413 crossref_primary_10_3390_app15148040 crossref_primary_10_1111_prd_12496 crossref_primary_10_1016_j_ijom_2019_10_011 crossref_primary_10_1111_cid_13241 crossref_primary_10_1111_prd_12531 crossref_primary_10_1016_j_cden_2019_02_008 crossref_primary_10_1016_j_prosdent_2021_08_009 crossref_primary_10_1186_s40729_025_00625_7 crossref_primary_10_2174_0118742106332436240820100241 crossref_primary_10_1007_s40496_022_00318_9 crossref_primary_10_1111_clr_14340 crossref_primary_10_1186_s40729_024_00541_2 crossref_primary_10_3390_dj12070202 crossref_primary_10_1111_cid_12629 crossref_primary_10_1111_jcpe_13981 crossref_primary_10_3390_jcm14155331 crossref_primary_10_3390_prosthesis5020033 crossref_primary_10_1111_ors_12662 crossref_primary_10_1186_s40729_020_00266_y crossref_primary_10_3390_polym14214482 crossref_primary_10_1111_jcpe_13061 crossref_primary_10_1111_jerd_13012 crossref_primary_10_3390_jcm9041143 crossref_primary_10_1016_j_ijom_2019_07_003 crossref_primary_10_3390_ma14143828 crossref_primary_10_1111_cid_13437 crossref_primary_10_1111_clr_70044 crossref_primary_10_3390_bioengineering9110627 crossref_primary_10_3390_gels10090593 crossref_primary_10_1111_jre_12980 crossref_primary_10_46889_JDHOR_2025_6210 crossref_primary_10_1002_cap_10234 crossref_primary_10_1111_clr_13755 crossref_primary_10_1186_s40729_022_00446_y crossref_primary_10_1016_j_ultrasmedbio_2024_06_002 crossref_primary_10_1186_s40729_020_00274_y crossref_primary_10_2478_asmj_2023_0002 crossref_primary_10_1088_1748_605X_ad6dc8 crossref_primary_10_3389_fcimb_2024_1472737 crossref_primary_10_1007_s00784_024_05613_6 crossref_primary_10_1016_j_colsurfb_2023_113318 crossref_primary_10_1097_JS9_0000000000001524 crossref_primary_10_3390_dj9110131 crossref_primary_10_1007_s00784_020_03213_8 crossref_primary_10_1016_j_jmst_2025_02_046 crossref_primary_10_1016_j_jormas_2023_101574 crossref_primary_10_1111_cid_70005 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.11607/jomi.5581 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Dentistry |
| EISSN | 1942-4434 |
| ExternalDocumentID | 28938030 |
| Genre | Meta-Analysis Systematic Review Journal Article |
| GroupedDBID | --- 0R~ 34H 53G 5GY 5RE 8RF AAWTL ABJNI ACGFO AENEX AFFNX ALMA_UNASSIGNED_HOLDINGS C94 CGR CUY CVF EBD EBS ECM EIF EJD F5P HZ~ NPM O9- P2P RQP SJN ZGI 7X8 |
| ID | FETCH-LOGICAL-c353t-6863b8c80f143c00d2573a4f796e076b59d7a13cc3fcef7d7c29145b3eaa33702 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 160 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000424190000006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1942-4434 |
| IngestDate | Sun Nov 09 12:42:05 EST 2025 Tue Jun 24 01:31:44 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c353t-6863b8c80f143c00d2573a4f796e076b59d7a13cc3fcef7d7c29145b3eaa33702 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 ObjectType-Undefined-4 |
| PMID | 28938030 |
| PQID | 1942736730 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1942736730 pubmed_primary_28938030 |
| PublicationCentury | 2000 |
| PublicationDate | 2018 January/February 20180101 |
| PublicationDateYYYYMMDD | 2018-01-01 |
| PublicationDate_xml | – month: 01 year: 2018 text: 2018 January/February |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | The International journal of oral and maxillofacial implants |
| PublicationTitleAlternate | Int J Oral Maxillofac Implants |
| PublicationYear | 2018 |
| SSID | ssj0021102 |
| Score | 2.5830674 |
| SecondaryResourceType | review_article |
| Snippet | The rate of developing soft tissue complications that accompany guided bone regeneration (GBR) procedures varies widely, from 0% to 45%. The present review was... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 41–50 |
| SubjectTerms | Alveolar Ridge Augmentation Bone Regeneration Guided Tissue Regeneration, Periodontal - adverse effects Humans Wound Healing |
| Title | Wound Healing Complications Following Guided Bone Regeneration for Ridge Augmentation: A Systematic Review and Meta-Analysis |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/28938030 https://www.proquest.com/docview/1942736730 |
| Volume | 33 |
| WOSCitedRecordID | wos000424190000006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT8MwDI6AIcGF92O8FCSuhW5Om5QLGoPBZdM0QOw2pXlMQ1o72AYXfjxO2w0uSEhceqgaNUoc219sfybkTMZccleiDKFvPKYQp0jNEfMoEMyKmIH0s2YTvNUS3W7ULi7cxkVa5UwnZopap8rdkV8g2EZLG6JAXo1ePdc1ykVXixYai6QE6Mo4qebdeRTBYZss2olDPcaAFfSkjlPt4iUdDs6DQFR-dy0zE9NY_-_kNsha4VzSWi4Nm2TBJFtk5cYlBLmebtvk89l1UaKu9ghNFq3_zCenDRSJ9MO9v5sOtNH0Ok0M7Zh-xkztvqHo4dKOq_CitWl_WJQtJZe0Rh_mjNA0DzdQiT9qmon0ZrwnO-SpcftYv_eK_gueggAmXihCiIUSvkWnSvm-xuMNklkehcbnYRxEmssKKAVWGcs1V9WowoIYjJQA3K_ukqUEZ7pPqNHM6tiiIWSIB3kUC1P1jVGAcIVrIcrkdLawPZRvF7SQiUmn49730pbJXr47vVFOxNFDsAgCtdTBH0YfklX0dUR-e3JEShZPtzkmy-odt-DtJBMcfLbazS_-_s83 |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Wound+Healing+Complications+Following+Guided+Bone+Regeneration+for+Ridge+Augmentation%3A+A+Systematic+Review+and+Meta-Analysis&rft.jtitle=The+International+journal+of+oral+and+maxillofacial+implants&rft.au=Lim%2C+Glendale&rft.au=Lin%2C+Guo-Hao&rft.au=Monje%2C+Alberto&rft.au=Chan%2C+Hsun-Liang&rft.date=2018-01-01&rft.issn=1942-4434&rft.eissn=1942-4434&rft.volume=33&rft.issue=1&rft.spage=41%E2%80%9350&rft_id=info:doi/10.11607%2Fjomi.5581&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1942-4434&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1942-4434&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1942-4434&client=summon |